Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.

[1]  Gary Box,et al.  The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 , 2010, Molecular Cancer Therapeutics.

[2]  Ian Collins,et al.  Identification of inhibitors of checkpoint kinase 1 through template screening. , 2009, Journal of medicinal chemistry.

[3]  Ian Collins,et al.  Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.

[4]  W. Pitt,et al.  Heteroaromatic rings of the future. , 2009, Journal of medicinal chemistry.

[5]  P. O'Connor,et al.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.

[6]  S. Ashwell,et al.  DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy , 2008, Clinical Cancer Research.

[7]  C. Britten,et al.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.

[8]  M. Garrett,et al.  CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? , 2007, Nature Reviews Cancer.

[9]  P. Lyne,et al.  Inhibitors of checkpoint kinases: from discovery to the clinic. , 2007, Current opinion in drug discovery & development.

[10]  A. Lochner,et al.  The many faces of H89: a review. , 2006, Cardiovascular drug reviews.

[11]  Nicolas Foloppe,et al.  Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. , 2005, Bioorganic & medicinal chemistry.

[12]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[13]  Jude Dunne,et al.  Comparison of on-chip and off-chip microfluidic kinase assay formats. , 2004, Assay and drug development technologies.

[14]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[15]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[16]  J. Huff,et al.  Piperazinylimidazo[1,2-a]pyrazines with selective affinity for in vitro alpha-adrenergic receptor subtypes. , 1983, Journal of medicinal chemistry.

[17]  Thomas P. Matthews and.  Design and Evaluation of 3,6-Di(hetero)aryl Imidazo[1,2-a]pyrazines as Inhibitors of Checkpoint and Other Kinases. , 2010 .